☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
SpringWorks Therapeutics
SpringWorks Therapeutics Reports the Results for Mirdametinib in P-IIb Trial to Treat Neurofibromatosis Type 1-Associated Plexifor...
November 17, 2023
SpringWorks Therapeutics Reports the US FDA Acceptance of NDA and Granted Priority Review of Nirogacestat for Desmoid Tumors
February 28, 2023
SpringWorks Therapeutics Reports First Patient Dosing in the P-II Trial of Nirogacestat for the Treatment of Ovarian Granulosa Cel...
September 30, 2022
SpringWorks Therapeutics Presents P-III (DeFi) Trial Results of Nirogacestat for the Treatment of Progressing Desmoid Tumors at ES...
August 22, 2022
Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma
October 6, 2020
Janssen Collaborates with SpringWorks to Evaluate Nirogacestat + Teclistamab for Relapsed or Refractory Multiple Myeloma
September 15, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.